{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:33:20Z","timestamp":1789472000152,"version":"build-2803163510"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW","award":["NNF21CC0073729"],"award-info":[{"award-number":["NNF21CC0073729"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>First-in-human trials mark a significant turning point in translational research, with novel therapies being tested in humans for the first time. Who should be included in FIH trials is a topic of ongoing debate amongst researchers, clinicians, ethicists, and sponsors. Yet, no comprehensive overview of the literature on this topic has been constructed before.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review of reasons was conducted, following the methodology outlined by Stretch and Sofaer for conducting systematic reviews of argument-based literature. Six online databases were consulted across various disciplines, including medicine (PubMed and Embase), philosophy (The Philosopher\u2019s Index and PhilPapers), and multidisciplinary studies (Web of Science and Academic Search Premier). Additionally, relevant books and book chapters were identified through the library of Leiden University. After data extraction and analysis, 80 publications were included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>181 reasons were identified amongst six potential participant categories: healthy volunteers, patients (general), patients with less advanced-stage diseases, patients with more advanced-stage diseases, vulnerable populations, and diverse participant groups. These reasons relate to six themes: non-maleficence, beneficence, scientific value, efficiency, respect for persons, and justice. This review highlights multiple challenges in the existing literature, including ambiguous or poorly defined reasons and unspecified use of moral theory, framework, or method, the use of beneficence as an important theme for including participants in FIH trials, and the complexity of identifying and defining vulnerable populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This review provides the first comprehensive overview of the reasons for and against including potential participant groups in FIH trials. The results highlight considerations that are relevant to reflect upon when determining and justifying participant selection for FIH trials. Additionally, this review offers guidance for further normative inquiry.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12967-025-06550-y","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:16:15Z","timestamp":1749647775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Who should be included in first-in-human trials? A systematic review of reasons"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8158-7126","authenticated-orcid":false,"given":"Lieke","family":"van Kempen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eelco J. P.","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"de Graeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"1","key":"6550_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cts.12582","volume":"12","author":"J Shen","year":"2019","unstructured":"Shen J, Swift B, Mamelok R, Pine S, Sinclair J, Attar M. Design and conduct considerations for first-in-human trials. Clin Transl Sci. 2019;12(1):6\u201319.","journal-title":"Clin Transl Sci"},{"key":"6550_CR2","volume-title":"The Oxford textbook of clinical research ethics","author":"R Steinbrook","year":"2008","unstructured":"Steinbrook R. The Gelsinger case. In: Emanuel EJ, editor. The Oxford textbook of clinical research ethics. England: Oxford University Press; 2008."},{"issue":"8","key":"6550_CR3","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.stemcr.2022.11.019","volume":"18","author":"RA Barker","year":"2023","unstructured":"Barker RA, Carpenter M, Jamieson CHM, Murry CE, Pellegrini G, Rao RC, et al. Lessons learnt, and still to learn, in first in human stem cell trials. Stem Cell Rep. 2023;18(8):1599\u2013609.","journal-title":"Stem Cell Rep"},{"key":"6550_CR4","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9627.1000113","author":"AR Chapman","year":"2011","unstructured":"Chapman AR. Addressing the ethical challenges of first in-human trials. J Clinic Res Bioeth. 2011. https:\/\/doi.org\/10.4172\/2155-9627.1000113.","journal-title":"J Clinic Res Bioeth"},{"issue":"1","key":"6550_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1748-720X.2009.00349.x","volume":"37","author":"R Dresser","year":"2009","unstructured":"Dresser R. First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless. J Law Med Ethics. 2009;37(1):38\u201350.","journal-title":"J Law Med Ethics"},{"issue":"2","key":"6550_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.drudis.2016.11.016","volume":"22","author":"M Habets","year":"2017","unstructured":"Habets M, van Delden JJM, Bredenoord AL. The unique status of first-in-human studies: strengthening the social value requirement. Drug Discov Today. 2017;22(2):471\u20135.","journal-title":"Drug Discov Today"},{"issue":"6","key":"6550_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1467-8519.2011.01858.x","volume":"26","author":"N Sofaer","year":"2012","unstructured":"Sofaer N, Strech D. The need for systematic reviews of reasons. Bioethics. 2012;26(6):315\u201328.","journal-title":"Bioethics"},{"issue":"1","key":"6550_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13287-022-02950-9","volume":"13","author":"D de Jongh","year":"2022","unstructured":"de Jongh D, Massey EK, Bunnik EM. Organoids: a systematic review of ethical issues. Stem Cell Res Ther. 2022;13(1):337.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"6550_CR9","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/bcp.15092","volume":"88","author":"HB de Las","year":"2022","unstructured":"de Las HB, Bouyoucef-Cherchalli D, Reeve L, Reichl A, Mandarino D, Flach S, et al. Healthy volunteers in first-in-human oncology drug development for small molecules. Br J Clin Pharmacol. 2022;88(4):1773\u201384.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"6550_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/21507740.2014.990544","volume":"6","author":"SA Hurst","year":"2015","unstructured":"Hurst SA, Mauron A, Momjian S, Burkhard PR. Ethical criteria for human trials of stem-cell-derived dopaminergic neurons in Parkinson\u2019s disease. AJOB Neurosci. 2015;6(1):52\u201360.","journal-title":"AJOB Neurosci"},{"issue":"1","key":"6550_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12967-018-1710-5","volume":"16","author":"JJ Karakunnel","year":"2018","unstructured":"Karakunnel JJ, Bui N, Palaniappan L, Schmidt KT, Mahaffey KW, Morrison B, et al. Reviewing the role of healthy volunteer studies in drug development. J Transl Med. 2018;16(1):336.","journal-title":"J Transl Med"},{"issue":"6","key":"6550_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/cpt.2009","volume":"109","author":"MW Leach","year":"2021","unstructured":"Leach MW, Clarke DO, Dudal S, Han C, Li C, Yang Z, et al. Strategies and recommendations for using a data-driven and risk-based approach in the selection of first-in-human starting dose: an international consortium for innovation and quality in pharmaceutical development (IQ) assessment. Clin Pharmacol Ther. 2021;109(6):1395\u2013415.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"6550_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1574884716666210427115820","volume":"17","author":"TV Iersel","year":"2022","unstructured":"Iersel TV, Courville J, Doorne CV, Koster RA, Fawcett C. The Patient motivation pyramid and patient-centricity in early clinical development. Curr Rev Clin Exp Pharmacol. 2022;17(1):8\u201317.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"1","key":"6550_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/cts.12703","volume":"13","author":"MA Ahmed","year":"2020","unstructured":"Ahmed MA, Patel C, Drezner N, Helms W, Tan W, Stypinski D. Pivotal considerations for optimal deployment of healthy volunteers in oncology drug development. Clin Transl Sci. 2020;13(1):31\u201340.","journal-title":"Clin Transl Sci"},{"key":"6550_CR15","doi-asserted-by":"publisher","first-page":"10751","DOI":"10.3389\/ti.2022.10751","volume":"35","author":"D de Jongh","year":"2022","unstructured":"de Jongh D, Massey EK, Cronin AJ, Schermer MHN, Bunnik EM. Early-phase clinical trials of bio-artificial organ technology: a systematic review of ethical issues. Transpl Int. 2022;35:10751.","journal-title":"Transpl Int"},{"issue":"2","key":"6550_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/medethics-2015-103115","volume":"43","author":"R Dresser","year":"2017","unstructured":"Dresser R. First-in-human HIV-remission studies: reducing and justifying risk. J Med Ethics. 2017;43(2):78\u201381.","journal-title":"J Med Ethics"},{"key":"6550_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/978-3-030-80443-5_16","volume-title":"Health care in contexts of risk, uncertainty, and hybridity","author":"AR Harris","year":"2022","unstructured":"Harris AR, Gilbert F. Military medicine research: incorporation of high risk of irreversible harms into a stratified risk framework for clinical trials. In: Messelken D, Winkler D, editors. Health care in contexts of risk, uncertainty, and hybridity. Cham: Springer International Publishing; 2022. p. 253\u201373."},{"issue":"3","key":"6550_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1086\/JCE201223310","volume":"23","author":"K Hug","year":"2012","unstructured":"Hug K, Hermer\u00e9n G. Which patient groups should be asked to participate in first-in-human trials of stem-cell-based therapies? J Clin Ethics. 2012;23(3):256\u201371.","journal-title":"J Clin Ethics"},{"issue":"11","key":"6550_CR19","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41436-021-01245-3","volume":"23","author":"AA Iyer","year":"2021","unstructured":"Iyer AA, Saade D, Bharucha-Goebel D, Foley AR, Averion G, Paredes E, et al. Ethical challenges for a new generation of early-phase pediatric gene therapy trials. Genet Med. 2021;23(11):2057\u201366.","journal-title":"Genet Med"},{"issue":"4","key":"6550_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/scrt474","volume":"5","author":"NM King","year":"2014","unstructured":"King NM, Perrin J. Ethical issues in stem cell research and therapy. Stem Cell Res Ther. 2014;5(4):85.","journal-title":"Stem Cell Res Ther"},{"key":"6550_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trsl.2016.05.006","volume":"177","author":"N Koonrungsesomboon","year":"2016","unstructured":"Koonrungsesomboon N, Laothavorn J, Karbwang J. Ethical considerations and challenges in first-in-human research. Transl Res. 2016;177:6\u201318.","journal-title":"Transl Res"},{"key":"6550_CR22","doi-asserted-by":"crossref","unstructured":"King NMP. Chapter 71\u2014Ethics in Regenerative Medicine and Transplantation. Elsevier. 2014.","DOI":"10.1016\/B978-0-12-398523-1.00071-9"},{"issue":"6","key":"6550_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s11017-024-09682-2","volume":"45","author":"C Bobier","year":"2024","unstructured":"Bobier C. Risky first-in-human clinical trials on medically fragile persons: owning the moral cost. Theor Med Bioeth. 2024;45(6):447\u201359.","journal-title":"Theor Med Bioeth"},{"issue":"1","key":"6550_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1017\/S0963180118000476","volume":"28","author":"F Bompart","year":"2019","unstructured":"Bompart F. Healthy volunteers for clinical trials in resource-poor settings: national registries can address ethical and safety concerns. Camb Q Healthc Ethics. 2019;28(1):134\u201343.","journal-title":"Camb Q Healthc Ethics"},{"issue":"3","key":"6550_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/15265161.2020.1867932","volume":"22","author":"S Hendriks","year":"2022","unstructured":"Hendriks S, Grady C, Wasserman D, Wendler D, Bianchi DW, Berkman BE. A new ethical framework for assessing the unique challenges of fetal therapy trials. Am J Bioeth. 2022;22(3):45\u201361.","journal-title":"Am J Bioeth"},{"issue":"11","key":"6550_CR26","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/sj.mt.6300316","volume":"15","author":"J Kimmelman","year":"2007","unstructured":"Kimmelman J. Stable ethics: enrolling non-treatment-refractory volunteers in novel gene transfer trials. Mol Ther. 2007;15(11):1904\u20136.","journal-title":"Mol Ther"},{"key":"6550_CR27","doi-asserted-by":"crossref","unstructured":"Collins JM. Chapter 31\u2014Phase I Clinical Studies. Second Edition. Principles of Clinical Pharmacology. Elsevier. 2007.","DOI":"10.1016\/B978-012369417-1\/50071-7"},{"issue":"1","key":"6550_CR28","first-page":"51","volume":"162","author":"C Petrini","year":"2011","unstructured":"Petrini C. From bench to bedside and to health policies: ethics in translational research. Clin Ter. 2011;162(1):51\u20139.","journal-title":"Clin Ter"},{"issue":"5","key":"6550_CR29","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0015-0282(03)02218-0","volume":"80","author":"L Dawson","year":"2003","unstructured":"Dawson L, Bateman-House AS, Mueller Agnew D, Bok H, Brock DW, Chakravarti A, et al. Safety issues in cell-based intervention trials. Fertil Steril. 2003;80(5):1077\u201385.","journal-title":"Fertil Steril"},{"key":"6550_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/1471-2458-11-811","volume":"11","author":"L Kapiriri","year":"2011","unstructured":"Kapiriri L, Lavery JV, Singer PA, Mshinda H, Babiuk L, Daar AS. The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries. BMC Public Health. 2011;11:811.","journal-title":"BMC Public Health"},{"issue":"2","key":"6550_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bcp.12096","volume":"76","author":"E Tranter","year":"2013","unstructured":"Tranter E, Peters G, Boyce M, Warrington S. Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe? Br J Clin Pharmacol. 2013;76(2):164\u201372.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"6550_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/cpt.2911","volume":"114","author":"Y Ji","year":"2023","unstructured":"Ji Y, Tan E, Hengelage T, Quinlan M, Hendriks BS. Exploratory food effect assessment in patients in early clinical development of oncology drugs. Clin Pharmacol Ther. 2023;114(2):288\u2013302.","journal-title":"Clin Pharmacol Ther"},{"key":"6550_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pneurobio.2013.04.003","volume":"110","author":"RA Barker","year":"2013","unstructured":"Barker RA, de Beaufort I. Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. Prog Neurobiol. 2013;110:63\u201373.","journal-title":"Prog Neurobiol"},{"key":"6550_CR34","doi-asserted-by":"publisher","DOI":"10.15168\/2284-4503-404","author":"M Daverio","year":"2019","unstructured":"Daverio M. Informed consent in translational\/clinical research. ethical issues according to international guidelines. Biolaw Journal-Rivista Di Biodiritto. 2019. https:\/\/doi.org\/10.15168\/2284-4503-404.","journal-title":"Biolaw Journal-Rivista Di Biodiritto"},{"issue":"4","key":"6550_CR35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1353\/pbm.2010.0007","volume":"53","author":"C Petrini","year":"2010","unstructured":"Petrini C. Ethical issues in translational research. Perspect Biol Med. 2010;53(4):517\u201333.","journal-title":"Perspect Biol Med"},{"issue":"1","key":"6550_CR36","doi-asserted-by":"publisher","first-page":"e12722","DOI":"10.1111\/xen.12722","volume":"29","author":"DJ Hurst","year":"2022","unstructured":"Hurst DJ, Padilla LA, Cooper DKC, Paris W. Scientific and psychosocial ethical considerations for initial clinical trials of kidney xenotransplantation. Xenotransplantation. 2022;29(1):e12722.","journal-title":"Xenotransplantation"},{"issue":"3","key":"6550_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11673-018-9865-6","volume":"15","author":"M Greene","year":"2018","unstructured":"Greene M, Master Z. Ethical issues of using CRISPR technologies for research on military enhancement. J Bioeth Inq. 2018;15(3):327\u201335.","journal-title":"J Bioeth Inq"},{"key":"6550_CR38","doi-asserted-by":"publisher","first-page":"10621","DOI":"10.3389\/ti.2022.10621","volume":"35","author":"EM Bunnik","year":"2022","unstructured":"Bunnik EM, de Jongh D, Massey E. Ethics of early clinical trials of bio-artificial organs. Transpl Int. 2022;35:10621.","journal-title":"Transpl Int"},{"issue":"2","key":"6550_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1467-8519.2011.01896.x","volume":"27","author":"RK Fung","year":"2013","unstructured":"Fung RK, Kerridge IH. Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells. Bioethics. 2013;27(2):89\u201396.","journal-title":"Bioethics"},{"issue":"1","key":"6550_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2217\/rme.12.112","volume":"8","author":"SL Niemansburg","year":"2013","unstructured":"Niemansburg SL, van Delden JJ, Dhert WJ, Bredenoord AL. Regenerative medicine interventions for orthopedic disorders: ethical issues in the translation into patients. Regen Med. 2013;8(1):65\u201373.","journal-title":"Regen Med"},{"issue":"10","key":"6550_CR41","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/ajt.15916","volume":"20","author":"RN Pierson","year":"2020","unstructured":"Pierson RN, Burdorf L, Madsen JC, Lewis GD, D\u2019Alessandro DA. Pig-to-human heart transplantation: who goes first? Am J Transplant. 2020;20(10):2669\u201374.","journal-title":"Am J Transplant"},{"key":"6550_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/jme-2024-110056","author":"J K\u00f6gel","year":"2024","unstructured":"K\u00f6gel J, Schmoeckel M, Marckmann G. Who shall go first? A multicriteria approach to patient selection for first clinical trials of cardiac xenotransplantation. J Med Ethics. 2024. https:\/\/doi.org\/10.1136\/jme-2024-110056.","journal-title":"J Med Ethics"},{"key":"6550_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030696","author":"JVP Devos","year":"2022","unstructured":"Devos JVP, Temel Y, Ackermans L, Visser-Vandewalle V, Onur OA, Schruers K, et al. Methodological considerations for setting up deep brain stimulation studies for new indications. JCM. 2022. https:\/\/doi.org\/10.3390\/jcm11030696.","journal-title":"JCM"},{"issue":"6","key":"6550_CR44","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.3747\/co.23.3214","volume":"23","author":"P Satalkar","year":"2016","unstructured":"Satalkar P, Elger BS, Shaw DM. Stakeholder views on participant selection for first-in-human trials in cancer nanomedicine. Curr Oncol. 2016;23(6):e530\u20137.","journal-title":"Curr Oncol"},{"issue":"2","key":"6550_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1353\/ken.2014.0017","volume":"24","author":"SP Hey","year":"2014","unstructured":"Hey SP, Kimmelman J. The risk-escalation model: a principled design strategy for early-phase trials. Kennedy Inst Ethics J. 2014;24(2):121\u201339.","journal-title":"Kennedy Inst Ethics J"},{"key":"6550_CR46","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511642364","volume-title":"Gene transfer and the ethics of first-in-human research: lost in translation","author":"J Kimmelman","year":"2009","unstructured":"Kimmelman J. Gene transfer and the ethics of first-in-human research: lost in translation. 1st ed. Cambridge: Cambridge University Press; 2009. https:\/\/doi.org\/10.1017\/CBO9780511642364.","edition":"1"},{"key":"6550_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-323-90120-8.00002-2","volume":"205","author":"J Kimmelman","year":"2024","unstructured":"Kimmelman J. Ethics of gene and cell therapy development for neurologic disorders. Handb Clin Neurol. 2024;205:111\u201321.","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"6550_CR48","doi-asserted-by":"publisher","first-page":"e1001010","DOI":"10.1371\/journal.pmed.1001010","volume":"8","author":"J Kimmelman","year":"2011","unstructured":"Kimmelman J, London AJ. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med. 2011;8(3):e1001010.","journal-title":"PLoS Med"},{"issue":"5","key":"6550_CR49","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.stem.2011.04.012","volume":"8","author":"F Bretzner","year":"2011","unstructured":"Bretzner F, Gilbert F, Baylis F, Brownstone RM. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell. 2011;8(5):468\u201375.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"6550_CR50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.stem.2011.04.008","volume":"8","author":"E Wirth","year":"2011","unstructured":"Wirth E, Lebkowski JS, Lebacqz K. Response to Frederic Bretzner et al. target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell. 2011;8(5):476\u20138.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"6550_CR51","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1017\/cjn.2020.113","volume":"47","author":"I Coates McCall","year":"2020","unstructured":"Coates McCall I, Minielly N, Bethune A, Lipsman N, McDonald PJ, Illes J. readiness for first-in-human neuromodulatory interventions. Can J Neurol Sci. 2020;47(6):785\u201392.","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"6550_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/21507740.2012.666323","volume":"3","author":"F Gilbert","year":"2012","unstructured":"Gilbert F, Harris AR, Kapsa RMI. Efficacy testing as a primary purpose of phase 1 clinical trials: is it applicable to first-in-human bionics and optogenetics trials? AJOB Neurosci. 2012;3(2):20\u20132.","journal-title":"AJOB Neurosci"},{"issue":"3","key":"6550_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/21507740.2014.911213","volume":"5","author":"F Gilbert","year":"2014","unstructured":"Gilbert F, Harris AR, Kapsa RMI. Controlling brain cells with light: ethical considerations for optogenetic clinical trials. AJOB Neurosci. 2014;5(3):3\u201311.","journal-title":"AJOB Neurosci"},{"issue":"1","key":"6550_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/rme.15.78","volume":"11","author":"M Habets","year":"2016","unstructured":"Habets M, van Delden JJM, Bredenoord AL. Studying the lay of the land: views and experiences of professionals in the translational pluripotent stem cell field. Regen Med. 2016;11(1):63\u201371.","journal-title":"Regen Med"},{"issue":"1","key":"6550_CR55","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12916-022-02710-9","volume":"20","author":"AR Harris","year":"2022","unstructured":"Harris AR, Walker MJ, Gilbert F. Ethical and regulatory issues of stem cell-derived 3-dimensional organoid and tissue therapy for personalised regenerative medicine. BMC Med. 2022;20(1):499.","journal-title":"BMC Med"},{"issue":"19\u201320","key":"6550_CR56","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1089\/ten.tea.2013.0332","volume":"20","author":"SL Niemansburg","year":"2014","unstructured":"Niemansburg SL, Teraa M, Hesam H, van Delden JJ, Verhaar MC, Bredenoord AL. Stem cell trials for cardiovascular medicine: ethical rationale. Tissue Eng Part A. 2014;20(19\u201320):2567\u201374.","journal-title":"Tissue Eng Part A"},{"issue":"6","key":"6550_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.stem.2008.05.005","volume":"2","author":"J Sugarman","year":"2008","unstructured":"Sugarman J. Human stem cell ethics: beyond the embryo. Cell Stem Cell. 2008;2(6):529\u201333.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"6550_CR58","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/mt.2008.13","volume":"16","author":"NM King","year":"2008","unstructured":"King NM, Cohen-Haguenauer O. En route to ethical recommendations for gene transfer clinical trials. Mol Ther. 2008;16(3):432\u20138.","journal-title":"Mol Ther"},{"issue":"6","key":"6550_CR59","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/j.1600-6143.2006.01336.x","volume":"6","author":"PP Rood","year":"2006","unstructured":"Rood PP, Cooper DK. Islet xenotransplantation: are we really ready for clinical trials? Am J Transplant. 2006;6(6):1269\u201374.","journal-title":"Am J Transplant"},{"issue":"5","key":"6550_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/15265161.2023.2296407","volume":"24","author":"M Laspro","year":"2024","unstructured":"Laspro M, Thys E, Chaya B, Rodriguez ED, Kimberly LL. First-in-human whole-eye transplantation: ensuring an ethical approach to surgical innovation. Am J Bioeth. 2024;24(5):59\u201373.","journal-title":"Am J Bioeth"},{"key":"6550_CR61","doi-asserted-by":"publisher","first-page":"1219591","DOI":"10.3389\/fphar.2023.1219591","volume":"14","author":"C Mundy","year":"2023","unstructured":"Mundy C, Bush J, Cheriyan J, Lorch U, Stringer S, Taubel J, et al. Association for human pharmacology in the pharmaceutical industry conference 2022: impending change, innovations and future challenges. Front Pharmacol. 2023;14:1219591.","journal-title":"Front Pharmacol"},{"key":"6550_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/npjparkd.2015.17","author":"RA Barker","year":"2015","unstructured":"Barker RA, Studer L, Cattaneo E, Takahashi J. G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson\u2019s disease. Npj Parkinsons Disease. 2015. https:\/\/doi.org\/10.1038\/npjparkd.2015.17.","journal-title":"Npj Parkinsons Disease"},{"issue":"12","key":"6550_CR63","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/mt.2016.202","volume":"24","author":"MG Habets","year":"2016","unstructured":"Habets MG, van Delden JJ, Niemansburg SL, Atkins HL, Bredenoord AL. One size fits all?: ethical considerations for examining efficacy in first-in-human pluripotent stem cell studies. Mol Ther. 2016;24(12):2039\u201342.","journal-title":"Mol Ther"},{"key":"6550_CR64","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymeth.2015.08.010","volume":"99","author":"HB Baker","year":"2016","unstructured":"Baker HB, McQuilling JP, King NM. Ethical considerations in tissue engineering research: case studies in translation. Methods. 2016;99:135\u201344.","journal-title":"Methods"},{"issue":"3","key":"6550_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1353\/ken.2012.0013","volume":"22","author":"AR Chapman","year":"2012","unstructured":"Chapman AR, Scala CC. Evaluating the first-in-human clinical trial of a human embryonic stem cell-based therapy. Kennedy Inst Ethics J. 2012;22(3):243\u201361.","journal-title":"Kennedy Inst Ethics J"},{"issue":"3","key":"6550_CR66","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1212\/WNL.0000000000003506","volume":"88","author":"DJ Cote","year":"2017","unstructured":"Cote DJ, Bredenoord AL, Smith TR, Ammirati M, Brennum J, Mendez I, et al. Ethical clinical translation of stem cell interventions for neurologic disease. Neurology. 2017;88(3):322\u20138.","journal-title":"Neurology"},{"issue":"5980","key":"6550_CR67","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1126\/science.1189369","volume":"328","author":"AJ London","year":"2010","unstructured":"London AJ, Kimmelman J, Emborg ME. Beyond access. vs protection in trials of innovative therapies. Science. 2010;328(5980):829\u201330.","journal-title":"Science"},{"issue":"5","key":"6550_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hast.1420","volume":"52","author":"MK Gusmano","year":"2022","unstructured":"Gusmano MK. Xenotransplantation clinical trials and the need for community engagement. Hastings Cent Rep. 2022;52(5):42\u20133.","journal-title":"Hastings Cent Rep"},{"issue":"5","key":"6550_CR69","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2217\/rme-2019-0126","volume":"15","author":"K Hug","year":"2020","unstructured":"Hug K. Understanding voluntariness of consent in first-in-human cell therapy trials. Regen Med. 2020;15(5):1647\u201360.","journal-title":"Regen Med"},{"issue":"18","key":"6550_CR70","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/cvr\/cvac180","volume":"118","author":"B Reichart","year":"2023","unstructured":"Reichart B, Cooper DKC, L\u00e4ngin M, T\u00f6njes RR, Pierson RN, Wolf E. Cardiac xenotransplantation: from concept to clinic. Cardiovasc Res. 2023;118(18):3499\u2013516.","journal-title":"Cardiovasc Res"},{"key":"6550_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jme-2024-110438","author":"RB Gibson","year":"2024","unstructured":"Gibson RB. Autonomy versus exclusion in xenotransplantation trials. J Med Ethics. 2024. https:\/\/doi.org\/10.1136\/jme-2024-110438.","journal-title":"J Med Ethics"},{"issue":"2","key":"6550_CR72","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.kint.2022.10.009","volume":"103","author":"PP Reese","year":"2023","unstructured":"Reese PP, Gelb BE, Parent B. Unique problems for the design of the first trials of transplanting porcine kidneys into humans. Kidney Int. 2023;103(2):239\u201342.","journal-title":"Kidney Int"},{"issue":"6","key":"6550_CR73","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/cts.13269","volume":"15","author":"T Burt","year":"2022","unstructured":"Burt T, Roffel AF, Langer O, Anderson K, DiMasi J. Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: is it time to change the drug development process in order to increase productivity? Clin Transl Sci. 2022;15(6):1355\u201379.","journal-title":"Clin Transl Sci"},{"key":"6550_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau8471","author":"SA Schneemann","year":"2020","unstructured":"Schneemann SA, Boers SN, van Delden JJM, Nieuwenhuis EES, Fuchs SA, Bredenoord AL. Ethical challenges for pediatric liver organoid transplantation. Sci Transl Med. 2020. https:\/\/doi.org\/10.1126\/scitranslmed.aau8471.","journal-title":"Sci Transl Med"},{"key":"6550_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jme-2024-110452","author":"DJ Hurst","year":"2024","unstructured":"Hurst DJ, Merlocco A, Padilla LA, Bobier C. Argument for allowing first-in-human cardiac xenotransplantation clinical trials in paediatric patients. J Med Ethics. 2024. https:\/\/doi.org\/10.1136\/jme-2024-110452.","journal-title":"J Med Ethics"},{"issue":"2","key":"6550_CR76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/ern.12.157","volume":"13","author":"SM Hewson","year":"2013","unstructured":"Hewson SM, Fehlings LN, Messih M, Fehlings MG. The challenges of translating stem cells for spinal cord injury and related disorders: what are the barriers and opportunities? Expert Rev Neurother. 2013;13(2):143\u201350.","journal-title":"Expert Rev Neurother"},{"key":"6550_CR77","first-page":"11","volume-title":"Developing first-in-human gene therapy clinical trials","author":"A Siobhan","year":"2020","unstructured":"Siobhan A, Joe A, Meredith H, Sarah HB, Addie S, Beachy SH, et al. Developing first-in-human gene therapy clinical trials. United States: National Academies Press; 2020. p. 11\u201322."},{"issue":"2","key":"6550_CR78","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/humrep\/dead258","volume":"39","author":"RT Mitchell","year":"2024","unstructured":"Mitchell RT, Ives J. Testicular tissue re-implantation and the \u2018hostile testis.\u2019 Hum Reprod. 2024;39(2):282\u20134.","journal-title":"Hum Reprod"},{"issue":"8","key":"6550_CR79","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.parkreldis.2015.05.011","volume":"21","author":"I de Melo-Mart\u00edn","year":"2015","unstructured":"de Melo-Mart\u00edn I, Hellmers N, Henchcliffe C. First-in-human cell transplant trials in Parkinson\u2019s disease: the need for an improved informed consent process. Parkinsonism Relat Disord. 2015;21(8):829\u201332.","journal-title":"Parkinsonism Relat Disord"},{"key":"6550_CR80","volume-title":"Perioperative neuroscience","author":"N Gupta","year":"2022","unstructured":"Gupta N. 15 - Ethical considerations in translational research. In: Prabhakar H, Mahajan C, Kapoor I, editors. Perioperative neuroscience. Amsterdam: Elsevier; 2022."},{"issue":"5","key":"6550_CR81","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.stem.2011.04.009","volume":"8","author":"JH Solbakk","year":"2011","unstructured":"Solbakk JH, Zoloth L. The tragedy of translation: the case of \u201cfirst use\u201d in human embryonic stem cell research. Cell Stem Cell. 2011;8(5):479\u201381.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"6550_CR82","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.addr.2011.01.002","volume":"63","author":"C Kurihara","year":"2011","unstructured":"Kurihara C. Ethical, legal, and social implications (ELSI) of microdose clinical trials. Adv Drug Deliv Rev. 2011;63(7):503\u201310.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"6550_CR83","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.maturitas.2013.01.001","volume":"74","author":"S Park","year":"2013","unstructured":"Park S, Oh D-S, Yoo H-R, Kang B. Age-adjusted reference values could be used for screening healthy older people in clinical trials. Maturitas. 2013;74(4):383\u20135.","journal-title":"Maturitas"},{"key":"6550_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jme-2024-110492","author":"L van Kempen","year":"2024","unstructured":"van Kempen L, de Vries MC, de Graeff N. A heart for everyone? The need to include diverse populations in first-in-human trials. J Med Eth. 2024. https:\/\/doi.org\/10.1136\/jme-2024-110492.","journal-title":"J Med Eth"},{"issue":"1","key":"6550_CR85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12910-022-00780-1","volume":"23","author":"K Dub\u00e9","year":"2022","unstructured":"Dub\u00e9 K, Kanazawa J, Patel H, Louella M, Sylla L, Sheehy J, et al. Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. BMC Med Ethics. 2022;23(1):39.","journal-title":"BMC Med Ethics"},{"issue":"5","key":"6550_CR86","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaci.2008.01.014","volume":"121","author":"SS Park","year":"2008","unstructured":"Park SS, Grayson MH. Clinical research: protection of the \u201cvulnerable\u201d? J Allergy Clin Immunol. 2008;121(5):1103\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"6550_CR87","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1200\/JCO.2016.67.9902","volume":"35","author":"J Kimmelman","year":"2017","unstructured":"Kimmelman J. Is participation in cancer phase I trials really therapeutic? J Clin Oncol. 2017;35(2):135\u20138.","journal-title":"J Clin Oncol"},{"key":"6550_CR88","unstructured":"National Academies of Sciences E, Medicine, Health, Medicine D, Board on Health Sciences P, Forum on Regenerative M. 2020. The National Academies Collection: Reports funded by National Institutes of Health. In: Beachy SH, Alper J, Hackmann M, Addie S (eds). Exploring Novel Clinical Trial Designs for Gene-Based Therapies: Proceedings of a Workshop. National Academies Press. Washington."},{"issue":"5","key":"6550_CR89","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/bioe.12683","volume":"34","author":"N Jacobs","year":"2020","unstructured":"Jacobs N. Two ethical concerns about the use of persuasive technology for vulnerable people. Bioethics. 2020;34(5):519\u201326.","journal-title":"Bioethics"},{"key":"6550_CR90","volume-title":"Vulnerability: new essays in ethics and feminist philosophy","author":"C Mackenzie","year":"2014","unstructured":"Mackenzie C. Vulnerability: new essays in ethics and feminist philosophy. England: OUP; 2014."},{"issue":"1","key":"6550_CR91","doi-asserted-by":"publisher","first-page":"34","DOI":"10.31486\/toj.19.0079","volume":"20","author":"BG Gordon","year":"2020","unstructured":"Gordon BG. Vulnerability in research: basic ethical concepts and general approach to review. Ochsner J. 2020;20(1):34\u20138.","journal-title":"Ochsner J"},{"key":"6550_CR92","doi-asserted-by":"publisher","DOI":"10.52214\/vib.v9i.11031","author":"G Strand","year":"2023","unstructured":"Strand G. Contextual vulnerability should guide fair subject selection in xenotransplantation clinical trials. VIB. 2023. https:\/\/doi.org\/10.52214\/vib.v9i.11031.","journal-title":"VIB"},{"issue":"4","key":"6550_CR93","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1467-8519.2008.00631.x","volume":"22","author":"SA Hurst","year":"2008","unstructured":"Hurst SA. Vulnerability in research and health care; describing the elephant in the room? Bioethics. 2008;22(4):191\u2013202.","journal-title":"Bioethics"},{"issue":"6","key":"6550_CR94","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/eahr.500036","volume":"41","author":"P Payne","year":"2019","unstructured":"Payne P. Including pregnant women in clinical research: practical guidance for institutional review boards. Ethics Hum Res. 2019;41(6):35\u201340.","journal-title":"Ethics Hum Res"},{"issue":"6","key":"6550_CR95","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/1740774520945601","volume":"17","author":"D Wendler","year":"2020","unstructured":"Wendler D. When and how to include vulnerable subjects in clinical trials. Clin Trials. 2020;17(6):696\u2013702.","journal-title":"Clin Trials"},{"issue":"6","key":"6550_CR96","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/bioe.13024","volume":"36","author":"G Birchley","year":"2022","unstructured":"Birchley G, Ives J. Fallacious, misleading and unhelpful: the case for removing systematic review from bioethics nomenclature. Bioethics. 2022;36(6):635\u201347.","journal-title":"Bioethics"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06550-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06550-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:04:14Z","timestamp":1749668654000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06550-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6550"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06550-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"649"}}